Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Boris Johnson

- PMLiVE

AstraZeneca opens new global strategic R&D centre in US

The new centre will be home to nearly 2,000 world-class researchers and scientists

- PMLiVE

AstraZeneca and Daiichi Sankyo to collaborate with Summit Therapeutics

This builds on a recently announced clinical collaboration between AstraZeneca and Summit to advance cancer treatments

- PMLiVE

AstraZeneca’s Tagrisso shows eight-year landmark survival in early-stage EGFR-mutated lung cancer

The results from a global phase 3 trial show the longest survival data ever reported in this setting

- PMLiVE

Moderna’s updated COVID-19 mRNA vaccine approved by MHRA

The updated vaccine will be available to eligible groups as part of the 2026/27 NHS vaccination programme

- PMLiVE

Pfizer and BioNTech’s XFG-adapted COVID-19 vaccine approved by US FDA

The 2026-2027 vaccine targets the XFG variant to more closely match current variants

- PMLiVE

AstraZeneca and Daiichi Sankyo’s Enhertu plus pertuzumab approved in EU as first-line treatment for breast cancer

This is the first new regimen in more than a decade for first-line treatment for this type of breast cancer

- PMLiVE

NICE recommends treatments for mantle cell lymphoma and chronic lymphocytic leukaemia

The treatments are for eligible adults in England and Wales

- PMLiVE

AstraZeneca’s Trixeo recommended by CHMP for approval in EU for asthma

Asthma affects over 360 million people worldwide, including over 40 million people in Europe

- PMLiVE

AstraZeneca agrees on $1.5bn deal with Dizal Pharmaceutical

The company will gain a novel oral treatment for lung cancer

- PMLiVE

AstraZeneca reports positive phase 3 data for tozorakimab in COPD

COPD affects nearly 400 million people globally and is the third leading cause of death worldwide

- PMLiVE

EMA’s PRIME scheme launches three major new features

The scheme supports the development of treatments targeting unmet medical needs in the EU

- PMLiVE

BMS’ Opdivo gets expanded FDA and EU approval for Hodgkin lymphoma

This type of cancer is the most common one diagnosed in teenagers

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links